⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NovaBridge Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
NovaBridge Biosciences
↗Rockville, Maryland, USA
NovaBridge Biosciences (formerly I-Mab) is a global biotechnology platform company that combines business development expertise with agile translational clinical development. The company focuses on identifying, accelerating, and advancing breakthrough pharmaceutical assets, particularly in the field of immuno-oncology.
Following its rebranding from I-Mab in October 2025, the company continues to operate as a public entity on the NASDAQ. Its strategic model emphasizes a hub-and-spoke approach to drug development, including the formation of subsidiaries like Visara, Inc. to advance specific therapeutic candidates.
CLASSIFICATION
SIZE & FINANCIALS
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:NBP
Market Cap:$0.22B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Bispecific antibody, Bifunctional biologic
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Visara, Inc.
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Wei Fu - Executive Chairman
LINKS
Website:novabridge.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NovaBridge Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.